---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-23-000067"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2023-04-21T23:59:59+00:00"
generated_at: "2026-06-16T21:37:29.566177+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# China NMPA accepts with priority review LianBio's NDA for mavacamten in oHCM

## Summary
- NMPA accepted NDA for mavacamten for symptomatic obstructive HCM in adults; priority review granted.
- NDA based on global Phase 3 EXPLORER-HCM trial and LianBio's Phase 1 PK study in Chinese volunteers.
- Blinded preliminary safety data from ongoing Phase 3 EXPLORER-CN trial supported early filing; topline results expected mid-2023.
- CEO states this is a pivotal moment as LianBio prepares to become a commercial-stage company.

## SEC filing metadata
- accession: 0001831283-23-000067
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2023-04-21T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000067/0001831283-23-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000067/lian-20230421.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-23-000067
- JSON: https://secwatch.observer/filing/0001831283-23-000067.json
- Plain text: https://secwatch.observer/filing/0001831283-23-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.